These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 27042677)

  • 1. Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis.
    Komori M; Lin YC; Cortese I; Blake A; Ohayon J; Cherup J; Maric D; Kosa P; Wu T; Bielekova B
    Ann Clin Transl Neurol; 2016 Mar; 3(3):166-79. PubMed ID: 27042677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cerebrospinal fluid markers reveal intrathecal inflammation in progressive multiple sclerosis.
    Komori M; Blake A; Greenwood M; Lin YC; Kosa P; Ghazali D; Winokur P; Natrajan M; Wuest SC; Romm E; Panackal AA; Williamson PR; Wu T; Bielekova B
    Ann Neurol; 2015 Jul; 78(1):3-20. PubMed ID: 25808056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Idebenone does not inhibit disability progression in primary progressive MS.
    Kosa P; Wu T; Phillips J; Leinonen M; Masvekar R; Komori M; Wichman A; Sandford M; Bielekova B
    Mult Scler Relat Disord; 2020 Oct; 45():102434. PubMed ID: 32784117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. No Early Effect of Intrathecal Rituximab in Progressive Multiple Sclerosis (EFFRITE Clinical Trial).
    Bonnan M; Ferrari S; Courtade H; Money P; Desblache P; Barroso B; Debeugny S
    Mult Scler Int; 2021; 2021():8813498. PubMed ID: 33763241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial.
    Hawker K; O'Connor P; Freedman MS; Calabresi PA; Antel J; Simon J; Hauser S; Waubant E; Vollmer T; Panitch H; Zhang J; Chin P; Smith CH;
    Ann Neurol; 2009 Oct; 66(4):460-71. PubMed ID: 19847908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis.
    Monson NL; Cravens PD; Frohman EM; Hawker K; Racke MK
    Arch Neurol; 2005 Feb; 62(2):258-64. PubMed ID: 15710854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor necrosis factor is elevated in progressive multiple sclerosis and causes excitotoxic neurodegeneration.
    Rossi S; Motta C; Studer V; Barbieri F; Buttari F; Bergami A; Sancesario G; Bernardini S; De Angelis G; Martino G; Furlan R; Centonze D
    Mult Scler; 2014 Mar; 20(3):304-12. PubMed ID: 23886826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progressive multiple sclerosis cerebrospinal fluid induces inflammatory demyelination, axonal loss, and astrogliosis in mice.
    Cristofanilli M; Rosenthal H; Cymring B; Gratch D; Pagano B; Xie B; Sadiq SA
    Exp Neurol; 2014 Nov; 261():620-32. PubMed ID: 25111532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peripheral B cell depletion and central proinflammatory cytokine reduction following repeated intrathecal administration of rituximab in progressive Multiple Sclerosis.
    Studer V; Rossi S; Motta C; Buttari F; Centonze D
    J Neuroimmunol; 2014 Nov; 276(1-2):229-31. PubMed ID: 25175066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamic effects of daclizumab in the intrathecal compartment.
    Komori M; Kosa P; Stein J; Zhao V; Blake A; Cherup J; Sheridan J; Wu T; Bielekova B
    Ann Clin Transl Neurol; 2017 Jul; 4(7):478-490. PubMed ID: 28695148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natalizumab in progressive MS: results of an open-label, phase 2A, proof-of-concept trial.
    Romme Christensen J; Ratzer R; Börnsen L; Lyksborg M; Garde E; Dyrby TB; Siebner HR; Sorensen PS; Sellebjerg F
    Neurology; 2014 Apr; 82(17):1499-507. PubMed ID: 24682973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Depletion of B lymphocytes from cerebral perivascular spaces by rituximab.
    Martin Mdel P; Cravens PD; Winger R; Kieseier BC; Cepok S; Eagar TN; Zamvil SS; Weber MS; Frohman EM; Kleinschmidt-Demasters BK; Montine TJ; Hemmer B; Marra CM; Stüve O
    Arch Neurol; 2009 Aug; 66(8):1016-20. PubMed ID: 19667224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid depletion of B lymphocytes by ultra-low-dose rituximab delivered intrathecally.
    Svenningsson A; Bergman J; Dring A; Vågberg M; Birgander R; Lindqvist T; Gilthorpe J; Bergenheim T
    Neurol Neuroimmunol Neuroinflamm; 2015 Apr; 2(2):e79. PubMed ID: 25745637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. B-cell-targeted therapy for systemic lupus erythematosus.
    Sabahi R; Anolik JH
    Drugs; 2006; 66(15):1933-48. PubMed ID: 17100405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intrathecal anti-CD20 efficiently depletes meningeal B cells in CNS autoimmunity.
    Lehmann-Horn K; Kinzel S; Feldmann L; Radelfahr F; Hemmer B; Traffehn S; Bernard CC; Stadelmann C; Brück W; Weber MS
    Ann Clin Transl Neurol; 2014 Jul; 1(7):490-6. PubMed ID: 25356419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-CD20 monoclonal antibody (Rituximab) and Cidofovir as successful treatment of an EBV-associated lymphoma with CNS involvement.
    Hänel M; Fiedler F; Thorns C
    Onkologie; 2001 Oct; 24(5):491-4. PubMed ID: 11694778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of antibodies in multiple sclerosis.
    Weber MS; Hemmer B; Cepok S
    Biochim Biophys Acta; 2011 Feb; 1812(2):239-45. PubMed ID: 20600871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis.
    Stüve O; Cepok S; Elias B; Saleh A; Hartung HP; Hemmer B; Kieseier BC
    Arch Neurol; 2005 Oct; 62(10):1620-3. PubMed ID: 16216948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of intrathecal rituximab in children with B cell lymphoid CD20+ malignancies: An international retrospective study.
    Ceppi F; Weitzman S; Woessmann W; Davies K; Lassaletta A; Reismüller B; Mellgren K; Uyttebroeck A; Maia I; Abdullah S; Miakova N; Glaser D; Cohn R; Abla O; Attarbaschi A; Alexander S
    Am J Hematol; 2016 May; 91(5):486-91. PubMed ID: 26872652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.